This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

5 Stocks Insiders are Scooping Up

Synageva BioPharma has a market cap of $1.19 billion and an enterprise value of $943 million. This stock trades at a premium valuation, with a price-to-sales of 100.66 and a price-to-book of 4.84. Its estimated growth rate for this year is 78.6%, and for next year it's pegged at -46.7%. This is a cash-rich company, since the total cash position on its balance sheet is $233.41 million and its total debt is zero.

A director and beneficial owner just bought 859,720 shares, or about $40.86 million worth of stock, at $47.53 per share.

From a technical perspective, GEVA is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has just started to bounce right above its 50-day moving average of $46.93 a share. That move is quickly pushing shares of GEVA within range of triggering a major breakout trade.

If you're in the bull camp on GEVA, then I would look for long-biased if this stock manages to break out above some near-term overhead resistance levels at $51.90 to $52.75 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 137,157 shares. If that breakout triggers soon, then GEVA will set up to re-test or possibly take out its next major overhead resistance levels at $56 to $58 a share. Keep in mind that any move above $58 would then push GEVA into new 52-week high territory, which is bullish technical price action.

Omeros

One name in the biopharmaceutical complex that insiders are warming up to here is Omeros (OMER). This company is engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Insiders are buying this stock into extreme weakness, since shares are off by 36% in the last six months.

Omeros has a market cap of $165 million and an enterprise value of $146 million. This stock trades at a premium valuation, with a price-to-sales of 28.98. Its estimated growth rate for this year is -22.5%, and for next year it's pegged at 22.2%. This is a cash-rich company, since the total cash position on its balance sheet is $30.63 million and its total debt is $15.05 million.

Stock quotes in this article: END, GEVA, OMER, LYV, NBY 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs